Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast Calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Breast cancer therapeutics industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Therapy trends
Chapter 3 Breast Cancer Therapeutics Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing burden of breast cancer
3.2.1.2 Increasing investments in R&D
3.2.1.3 Launch of several diagnostic and screening programs
3.2.1.4 Favorable insurance and reimbursement policies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse-effects associated with breast cancer drugs
3.2.2.2 High cost of drugs
3.2.3 Growth potential analysis
3.2.4 By therapy
3.3 COVID-19 impact analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Breast Cancer Therapeutics Market Estimates and Forecast, By Therapy, 2018-2032 (USD Million)
5.1 Key trends, by therapy
5.2 Targeted therapy
5.3 Hormonal therapy
5.4 Chemotherapy
5.5 Immunotherapy
Chapter 6 Breast Cancer Therapeutics Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
6.1 Key trends, by region
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 Germany
6.3.2 UK
6.3.3 France
6.3.4 Spain
6.3.5 Italy
6.3.6 Rest of Europe
6.4 Asia Pacific
6.4.1 China
6.4.2 Japan
6.4.3 India
6.4.4 Australia
6.4.5 Rest of Asia Pacific
6.5 Latin America
6.5.1 Brazil
6.5.2 Mexico
6.5.3 Rest of Latin America
6.6 Middle East & Africa
6.6.1 South Africa
6.6.2 Saudi Arabia
6.6.3 Rest of Middle East & Africa
Chapter 7 Company Profiles
7.1 AstraZeneca plc.
7.2 Eli Lilly & Co, Inc.
7.3 Pfizer, Inc.
7.4 Novartis AG
7.5 Amgen
7.6 F. Hoffmann La Roche AG
7.7 Merck & Co, Inc.
7.8 Gilead Sciences, Inc.
7.9 Eisai Co., Ltd.
7.10 Macrogenics, Inc.
7.11 Stemline Therapeutics, Inc.
